TWM473840U - Composition structure for inhibiting bacterial infection of gastrointestinal tract - Google Patents

Composition structure for inhibiting bacterial infection of gastrointestinal tract Download PDF

Info

Publication number
TWM473840U
TWM473840U TW102210595U TW102210595U TWM473840U TW M473840 U TWM473840 U TW M473840U TW 102210595 U TW102210595 U TW 102210595U TW 102210595 U TW102210595 U TW 102210595U TW M473840 U TWM473840 U TW M473840U
Authority
TW
Taiwan
Prior art keywords
composition
composition structure
activated carbon
silver
layer
Prior art date
Application number
TW102210595U
Other languages
Chinese (zh)
Inventor
Tse-Hao Ko
Original Assignee
Tse-Hao Ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tse-Hao Ko filed Critical Tse-Hao Ko
Priority to TW102210595U priority Critical patent/TWM473840U/en
Publication of TWM473840U publication Critical patent/TWM473840U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

用於抑制腸胃道細菌感染的組成物結構 Composition structure for inhibiting bacterial infection of gastrointestinal tract

本創作關於一種組成物結構,且特別攸關一種用於抑制腸胃道細菌感染的組成物結構。 This work relates to a composition structure, and in particular to a composition structure for inhibiting bacterial infection of the gastrointestinal tract.

因現代人生活步調緊張,於是易造成腸胃道不適,進而有罹患腸胃道相關疾病的高風險。造成這些疾病的主因部分是腸胃道細菌的感染,如大腸桿菌(Escherichia coli)的感染會造成出血性結腸炎、金黃色葡萄球菌(Staphylococcus aureus)的感染會造成急性腸胃炎、幽門螺旋桿菌(Helicobacter pylori)的感染會造成腸胃炎、胃潰瘍、十二指腸潰瘍、胃淋巴瘤或胃癌。 Because of the tight pace of modern life, it is easy to cause gastrointestinal discomfort, and then there is a high risk of suffering from gastrointestinal related diseases. The main cause of these diseases is the infection of gastrointestinal bacteria. Escherichia coli infection can cause hemorrhagic colitis, Staphylococcus aureus infection can cause acute gastroenteritis, Helicobacter Helicobacter Infection with pylori can cause gastroenteritis, gastric ulcer, duodenal ulcer, gastric lymphoma or stomach cancer.

目前,腸胃道細菌感染的臨床治療是以投予病患抗生素為主。舉例而言,幽門螺旋桿菌感染的治療主要是採用「三合一療法」,此方法是投予病患二種不同的抗生素,像是克拉黴素(Clarithromycin)、阿莫西林(Amoxicillin)、四環黴素(Tetracycline)、咪唑尼達(Metronidazole)、以及一種胃酸分泌抑制劑,像是奧美拉唑(Omeprazole)、蘭素拉唑(Lansoprazole),抗生素的投予須持續一個禮拜(有必要時,可延長至二個禮拜),胃酸分泌抑制劑的投予須持續二個月(有必要時,可延長至四個月)。但整個治療過程中,大多數的病患可能會對藥物產生毒副作用,例如:頭暈、口苦、長舌苔、腹脹、 味覺遲鈍、噁心、腹瀉;而且,加上治療過程相當冗長,所以病患易對治療產生不順從性,而影響疾病的治癒。另一方面,病患長期服用抗生素後,可能造成幽門螺旋桿菌產生抗藥性,抗藥性的結果不僅影響疾病的治癒,更影響往後疾病治療的藥物選擇。 At present, the clinical treatment of gastrointestinal bacterial infection is based on the administration of antibiotics to patients. For example, the treatment of Helicobacter pylori infection is mainly the use of "three-in-one therapy", which involves administering two different antibiotics to the patient, such as Clarithromycin, Amoxicillin, and IV. Tetracycline, Metronidazole, and a gastric acid secretion inhibitor, such as Omeprazole and Lansoprazole, must be administered for one week (necessary) The time can be extended to two weeks. The administration of gastric acid secretion inhibitors must last for two months (if necessary, it can be extended to four months). However, during the entire treatment period, most patients may have toxic side effects on the drug, such as: dizziness, bitterness, long tongue coating, bloating, Taste dullness, nausea, diarrhea; and, coupled with a rather lengthy treatment process, patients are prone to non-compliance with treatment and affect the cure of the disease. On the other hand, long-term use of antibiotics may cause Helicobacter pylori resistance, and the results of drug resistance not only affect the cure of the disease, but also affect the choice of drugs for future treatment.

綜上可知,用於抑制腸胃道細菌感染的藥物普遍存在著毒副作用及/或抗藥性的問題,因而確實有必要開發多種不同的藥物,以提供來抑制腸胃道細菌的感染。 In summary, drugs for inhibiting gastrointestinal bacterial infections generally have toxic side effects and/or drug resistance problems, so it is indeed necessary to develop a variety of different drugs to provide inhibition of gastrointestinal bacterial infections.

本創作之目的是在提出一種新穎的組成物結構,此組成物結構可抑制腸胃道細菌的感染。 The purpose of this creation is to propose a novel composition structure that inhibits infection of gastrointestinal bacteria.

為達成上述及/或其他目的,本創作提出了一種用於抑制腸胃道細菌感染的組成物結構,其包含:一主體層以及一活性顆粒。主體層是由碳質材料所製成的,而活性顆粒是承載於主體層的一表面且是由銀、金、鋁、鋅、銅及二氧化鈦所組成之群組所製成的。 To achieve the above and/or other objects, the present invention proposes a composition structure for inhibiting bacterial infection of the gastrointestinal tract comprising: a host layer and an active particle. The main layer is made of a carbonaceous material, and the active particles are carried on a surface of the main body layer and are made of a group of silver, gold, aluminum, zinc, copper and titanium dioxide.

根據本創作,主體層會主動地吸附腸胃道細菌,並利用活性顆粒殺除被吸附及/或未被吸附的腸胃道細菌。透過此機制,本創作的組成物結構可有效地抑制腸胃道細菌的感染,而可作為抑制腸胃道細菌感染的藥物。 According to the present creation, the main layer actively adsorbs gastrointestinal bacteria and uses active particles to kill gastrointestinal bacteria that are adsorbed and/or unadsorbed. Through this mechanism, the composition of the present composition can effectively inhibit the infection of gastrointestinal bacteria, and can be used as a drug for inhibiting bacterial infection of the gastrointestinal tract.

(1)‧‧‧主體層 (1) ‧ ‧ main body

(11)‧‧‧孔洞 (11)‧‧‧ holes

(2)‧‧‧活性顆粒 (2) ‧‧‧active granules

第一A至一C圖為示意圖,說明著本創作之用於抑制腸胃道細菌感染的組成物結構。 The first A to C diagrams are schematic diagrams showing the composition of the composition for inhibiting bacterial infection of the gastrointestinal tract.

第二圖為一胃內視鏡照片,說明著一幽門螺旋桿菌造成之胃潰瘍 的病患於服用本創作之組成物結構7天後的治療狀況。 The second picture is a photo of a stomach endoscope showing the gastric ulcer caused by a Helicobacter pylori The condition of the patient after 7 days of taking the composition of the present composition.

第三圖為一掃描式電子顯微鏡照片(X5,000),說明著製備例1之組成物結構的外觀。 The third figure is a scanning electron micrograph (X5,000) illustrating the appearance of the composition of Preparation Example 1.

第四圖為一掃描式電子顯微鏡照片(X1,000),說明著製備例3之組成物結構中的活性碳纖維主體層可吸附大腸桿菌。 The fourth figure is a scanning electron micrograph (X1,000), which shows that the activated carbon fiber main layer in the composition structure of Preparation Example 3 can adsorb Escherichia coli.

第五圖為一掃描式電子顯微鏡照片(X1,000),說明著製備例3之組成物結構中的活性碳纖維主體層可吸附幽門螺旋桿菌。 The fifth drawing is a scanning electron micrograph (X1,000) showing that the active carbon fiber main layer in the composition structure of Preparation Example 3 can adsorb H. pylori.

本創作人於美國發明專利公開號2007/0122463中,已揭示一種抗微生物組合物,且更指出此抗微生物組合物可主動殺死微生物,但其僅例示用於處理皮膚外傷的用途。另一方面,抗微生物組合物中的活性碳已用於毒藥物中毒患者的洗胃,以於患者胃部內吸附毒藥物。而且,抗微生物組合物中的銀已被歐盟合法地作為編號E174食用色素的添加劑。也就是說,無論是活性碳或銀在我們的日常生活中均為可食用的。本創作人認為活性碳及銀結合的組成物結構如果可以有效地殺除腸胃道細菌,此組成物結構應可抑制腸胃道細菌的感染。並且,基於此組成物結構中的各別組份具有可食用的特性,本創作人更認為此組成物結構應無毒副作用及/或抗藥性的問題。 An antimicrobial composition has been disclosed by the present inventors in U.S. Patent Publication No. 2007/0122463, and it is further indicated that the antimicrobial composition can actively kill microorganisms, but it is merely illustrative of the use for treating skin trauma. On the other hand, activated carbon in the antimicrobial composition has been used for gastric lavage in patients with toxic drug poisoning to adsorb toxic drugs in the stomach of the patient. Moreover, silver in the antimicrobial composition has been legally used by the European Union as an additive to the numbered E174 food coloring. In other words, both activated carbon and silver are edible in our daily lives. The creator believes that if the structure of the composition of activated carbon and silver is effective in killing gastrointestinal bacteria, the structure of the composition should inhibit the infection of gastrointestinal bacteria. Further, based on the edible characteristics of the respective components in the composition of the composition, the present inventors believe that the composition of the composition should have no problem of toxic side effects and/or drug resistance.

於是,本創作提出一種用於抑制腸胃道細菌感染的組成物結構,而此組成物結構如第一A至一C所示,其含有一主體層(1)及一活性顆粒(2)。主體層(1)是由碳質材料所製成的,活性顆粒(2)是承載於主體層(1)的一表面且是由銀、金、鋁、鋅、銅及二氧化鈦所組成之群組所製成的。 Thus, the present invention proposes a composition structure for inhibiting bacterial infection of the gastrointestinal tract, and the composition has a structure as shown in the first A to C, which contains a host layer (1) and an active particle (2). The main body layer (1) is made of a carbonaceous material, and the active particles (2) are a group carried on a surface of the main body layer (1) and composed of silver, gold, aluminum, zinc, copper and titanium dioxide. Made of.

從下文的實施例可知,本創作的組成物結構是利用由碳質材料所製成的主體層(1)吸附腸胃道細菌,例如:大腸桿菌、金黃色葡萄球菌或幽門螺旋桿菌,再利用活性顆粒(2)殺除被吸附及/或其餘未被吸附的腸胃道細菌。這麼一來,本創作的組成物結構可有效地清除腸胃道細菌,而可抑制腸胃道細菌的感染。如第二圖所示,本創作的組成物結構還可治療或預防腸胃道細菌感染造成的疾病,例如:大腸桿菌感染造成的出血性結腸炎、金黃色葡萄球菌感染造成的急性腸胃炎、幽門螺旋桿菌感染造成的胃潰瘍、腸胃炎或十二指腸潰瘍。 As can be seen from the examples below, the composition of the present invention is a structure in which a main layer (1) made of a carbonaceous material is used to adsorb gastrointestinal bacteria such as Escherichia coli, Staphylococcus aureus or Helicobacter pylori, and the activity is reused. The granules (2) kill the gastrointestinal bacteria that are adsorbed and/or remain unadsorbed. In this way, the composition of the present composition can effectively remove gastrointestinal bacteria, but can inhibit the infection of gastrointestinal bacteria. As shown in the second figure, the composition of the present composition can also treat or prevent diseases caused by bacterial infections in the gastrointestinal tract, such as hemorrhagic colitis caused by Escherichia coli infection, acute gastroenteritis caused by Staphylococcus aureus infection, pylorus A gastric ulcer, gastroenteritis or duodenal ulcer caused by a spirochete infection.

根據未提出的資料,於餵食大鼠(rat)本創作之組成物結構後的第30天,大鼠的肝臟、腎臟及血液內未發現任何活性顆粒(2)的成分存在,但僅在大鼠排出的糞便中發現微量之活性顆粒(2)的成分。此現象說明著,本創作之組成物結構中的活性顆粒(2)不會殘留於大鼠體內。 According to the unreported data, on the 30th day after feeding the composition of the rat composition, no active granules (2) were found in the liver, kidney and blood of the rats, but only in the large A trace amount of the active granule (2) component was found in the feces discharged from the mouse. This phenomenon indicates that the active particles (2) in the composition of the present composition do not remain in the rat.

製成主體層(1)的碳質材料不限於任何種類,只要主體層(1)能吸附腸胃道細菌即可,而其例子可以為但不限於,活性碳纖維、活性碳粉、木炭、竹炭粒、碳黑、石墨粉、膨脹石墨粉、或是酚醛樹脂或人造樹脂製成的碳粉。而且主體層(1)的比表面積較佳地為400至2,500m2/g。活性顆粒(2)不限於任何外觀尺寸,只要能殺除腸胃道細菌即可,而其粒徑較佳地為1nm至500μm,更佳地為5nm至10μm。 The carbonaceous material to be formed into the main layer (1) is not limited to any kind as long as the main layer (1) can adsorb gastrointestinal bacteria, and examples thereof may be, but not limited to, activated carbon fibers, activated carbon powder, charcoal, and bamboo charcoal particles. , carbon black, graphite powder, expanded graphite powder, or carbon powder made of phenolic resin or synthetic resin. Further, the specific surface area of the main layer (1) is preferably from 400 to 2,500 m 2 /g. The active particles (2) are not limited to any external size as long as they can kill gastrointestinal bacteria, and the particle diameter thereof is preferably from 1 nm to 500 μm, more preferably from 5 nm to 10 μm.

如第一A至一C圖所示,為促進主體層(1)吸附腸胃道細菌的效果,主體層(1)可以有孔洞(11)。一般來說,主體層(1)除了可吸附腸胃道細菌外,還可能吸附個體內的其他物質(如:各 種維他命)或益生菌,而為了避免此現象發生,孔洞(11)的半徑較佳地為大於0nm而未超過2.5nm,更佳地為0.5至2.3nm。 As shown in the first A to C diagram, in order to promote the effect of the main layer (1) on the adsorption of gastrointestinal bacteria, the main layer (1) may have pores (11). In general, the main layer (1), in addition to adsorbing gastrointestinal bacteria, may also adsorb other substances in the individual (eg: each Vitamins or probiotics, and to avoid this, the radius of the pores (11) is preferably greater than 0 nm and not more than 2.5 nm, more preferably 0.5 to 2.3 nm.

如第一A至一C圖所示,主體層(1)不限於任何形狀,例如圓柱狀、球狀、片層狀或其他不規則形狀。而且,主體層(1)的形狀可能會與製成主體層(1)的碳質材料有關。舉例來說,碳質材料為活性碳纖維時,主體層(1)的形狀為圓柱狀;碳質材料為活性碳粉、竹炭粒或石墨粉時,主體層(1)的形狀為球狀;碳質材料為木炭時,主體層(1)的形狀為片層狀。 As shown in the first A to C diagram, the body layer (1) is not limited to any shape such as a cylindrical shape, a spherical shape, a lamellar shape or other irregular shape. Moreover, the shape of the body layer (1) may be related to the carbonaceous material from which the body layer (1) is formed. For example, when the carbonaceous material is activated carbon fiber, the shape of the main layer (1) is cylindrical; when the carbonaceous material is activated carbon powder, bamboo charcoal or graphite powder, the shape of the main layer (1) is spherical; carbon When the material is charcoal, the shape of the main layer (1) is lamellar.

為方便經口地投予本創作的組成物結構至個體,當碳質材料為活性碳纖維時,主體層(1)的特徵如下:長度為大於0mm而未超過0.1mm、直徑為大於0μm而未超過10μm。 In order to facilitate the oral administration of the composition of the present composition to the individual, when the carbonaceous material is activated carbon fiber, the main layer (1) is characterized as follows: the length is greater than 0 mm but not more than 0.1 mm, and the diameter is greater than 0 μm. More than 10μm.

為避免活性顆粒(2)於個體內從主體層(1)上脫落而造成個體的傷害,以主體層(1)的重量為基準,活性顆粒(2)的重量百分比較佳地為0.001至15wt%,且活性顆粒(2)在水中的析出量較佳地為大於0ppm而未超過100ppm。 In order to avoid damage to the individual caused by the active particles (2) falling off the body layer (1) in the individual, the weight percentage of the active particles (2) is preferably 0.001 to 15 wt% based on the weight of the main layer (1). %, and the amount of precipitation of the active particles (2) in water is preferably more than 0 ppm and not more than 100 ppm.

特別說明的是,本創作的組成物結構可透過本技術領域熟悉的含浸、噴灑或電鍍方式將活性顆粒(2)承載於主體層(1)的表面,或者透過本創作人於美國發明專利公告號7,687,433揭露的方法。而且,當碳質材料為活性碳纖維時,可先利用聚丙烯腈(Polyacrylonitrile,PAN)系纖維、瀝青纖維、酚醛纖維、木質素纖維或螺縈(Rayon)纖維為其原料,再利用本技術領域熟悉的處理方式轉化原料成活性碳纖維。有關本創作之組成物結構的詳細製造過程將於後文的實施例中提出具體說明。 In particular, the composition of the present invention can be carried on the surface of the body layer (1) by impregnation, spraying or electroplating which is well known in the art, or by the present inventor in the US invention patent notice. No. 7,687,433 discloses the method. Moreover, when the carbonaceous material is activated carbon fiber, polyacrylonitrile (PAN) fiber, asphalt fiber, phenolic fiber, lignin fiber or Rayon fiber may be used as a raw material, and the technical field is reused. A familiar treatment mode converts the raw materials into activated carbon fibers. A detailed manufacturing process for the composition of the present composition will be specifically described in the following examples.

茲以下述實施例,以進一步例示說明本創作。 The following examples are presented to further illustrate this creation.

<製備例1> <Preparation Example 1>

提供一聚丙烯腈系活性碳纖維布,其性質如下:布重為70g/m2、經緯密為16根/in、BET比表面積為1,630m2/g、密度為2.09g/m3、碳含量為85wt%、銀含量為0wt%。 Providing a polyacrylonitrile-based activated carbon fiber cloth having the following properties: a cloth weight of 70 g/m 2 , a warp and weft density of 16 pieces/in, a BET specific surface area of 1,630 m 2 /g, a density of 2.09 g/m 3 , and a carbon content. It is 85 wt% and the silver content is 0 wt%.

於真空環境下,將纖維布浸泡在濃度0.1M的硝酸銀水溶液(pH3.8)中5小時,以讓銀離子還原成附著於纖維布上的銀塊。乾燥附有銀塊的纖維布,以去除其殘留的水分。 The fiber cloth was immersed in a 0.1 M aqueous silver nitrate solution (pH 3.8) for 5 hours in a vacuum atmosphere to reduce silver ions to silver nuggets attached to the fiber cloth. The fiber cloth with the silver block is dried to remove the residual moisture.

將乾燥後的纖維布置於溫度400℃且充滿氮氣的高溫爐內90分鐘,以讓銀塊裂解成分散附著於纖維布上的銀顆粒。 The dried fibers were placed in a high temperature furnace filled with nitrogen at a temperature of 400 ° C for 90 minutes to crack the silver nump into silver particles dispersed on the fiber cloth.

將附有銀顆粒的纖維布研磨、粉碎與過篩,而得到一承載有銀顆粒的活性碳纖維主體層(如第二圖所示,銀顆粒及活性碳纖維主體層的整體稱作為「組成物結構」)。 Grinding, pulverizing and sieving the fiber cloth with silver particles to obtain a main layer of activated carbon fiber carrying silver particles (as shown in the second figure, the silver particles and the active carbon fiber main layer are collectively referred to as "composition structure" ").

本製備例的組成物結構具有以下特徵:BET比表面積約為1,200m2/g、密度約為2.13/m3、碳含量約為64wt%、銀含量約為12.5wt%;組成物結構中的主體層具有以下特徵:長度約為0.1mm、直徑約為6.0μm、孔洞直徑約為2.41nm;組成物中的銀顆粒具有以下特徵:在水中的析出量約為15.75ppm。 The composition structure of this preparation example has the following characteristics: a BET specific surface area of about 1,200 m 2 /g, a density of about 2.13 / m 3 , a carbon content of about 64 wt%, and a silver content of about 12.5% by weight; The bulk layer has the following features: a length of about 0.1 mm, a diameter of about 6.0 μm, and a pore diameter of about 2.41 nm; the silver particles in the composition have the following characteristics: the amount of precipitation in water is about 15.75 ppm.

<製備例2> <Preparation Example 2>

於真空環境下,將一如製備例1使用的聚丙烯腈系活性碳纖維布浸泡在濃度0.1M的硝酸銀水溶液(pH3.8)中5小時,以讓銀離子還原成附著於纖維布上的銀塊。乾燥附有銀塊的纖維布,以去除 其殘留的水分。 The polyacrylonitrile-based activated carbon fiber cloth used in Preparation Example 1 was immersed in a 0.1 M silver nitrate aqueous solution (pH 3.8) for 5 hours in a vacuum atmosphere to reduce silver ions to silver blocks attached to the fiber cloth. . Dry the fiber cloth with silver block to remove Its residual moisture.

將乾燥後的纖維布置於溫度400℃且充滿氮氣的高溫爐內90分鐘,以讓銀塊裂解成分散附著於纖維布上的銀顆粒。 The dried fibers were placed in a high temperature furnace filled with nitrogen at a temperature of 400 ° C for 90 minutes to crack the silver nump into silver particles dispersed on the fiber cloth.

以流速4.5公升/分鐘的水清洗附有銀顆粒的纖維布120小時,以去除未附著於纖維布上的銀顆粒。乾燥清洗後的纖維布。 The fiber cloth with silver particles was washed with water at a flow rate of 4.5 liters/min for 120 hours to remove silver particles not attached to the fiber cloth. Dry the cleaned fiber cloth.

將乾燥後的纖維布研磨、粉碎與過篩,而得到一承載有銀顆粒的活性碳纖維主體層(銀顆粒及活性碳纖維主體層的整體稱作為「組成物結構」)。 The dried fiber cloth is ground, pulverized, and sieved to obtain an active carbon fiber main layer (silver particles and an active carbon fiber main layer collectively referred to as a "composition structure") carrying silver particles.

本製備例的組成物結構具有以下特徵:BET比表面積約為1,220m2/g、密度約為2.13/m3、銀含量約為0.03wt%;組成物結構中的主體層具有以下特徵:長度約為0.1mm、直徑約為6.0μm、孔洞直徑約為2.41nm;組成物結構中的銀顆粒具有以下特徵:在水中的析出量約為10.04ppm。 The composition structure of this preparation example has the following characteristics: a BET specific surface area of about 1,220 m 2 /g, a density of about 2.13 / m 3 , and a silver content of about 0.03 wt%; the bulk layer in the composition structure has the following characteristics: length It is about 0.1 mm, has a diameter of about 6.0 μm, and has a pore diameter of about 2.41 nm; the silver particles in the composition structure have the following characteristics: the amount of precipitation in water is about 10.04 ppm.

<製備例3> <Preparation Example 3>

提供一酚醛系活性碳纖維氈,其性質如下:氈重為100g/m2、BET比表面積為1,420m2/g、密度為2.032g/m3、碳含量為85wt%、銀含量為0wt%。 A phenolic activated carbon fiber felt having the following properties: a felt weight of 100 g/m 2 , a BET specific surface area of 1,420 m 2 /g, a density of 2.032 g/m 3 , a carbon content of 85 wt%, and a silver content of 0 wt%.

於真空環境下,將纖維氈浸泡在濃度0.001M的硝酸銀水溶液(pH6.4)中5小時,以讓銀離子還原成附著於纖維氈上的銀塊。乾燥附有銀塊的纖維氈,以去除其殘留的水分。 The fiber mat was immersed in a 0.001 M aqueous solution of silver nitrate (pH 6.4) for 5 hours under vacuum to reduce the silver ions to silver nuggets attached to the fiber mat. The fiber mat with the silver block is dried to remove the residual moisture.

將乾燥後的纖維氈置於溫度400℃且充滿氮氣的高溫爐內90分鐘,以讓銀塊裂解成分散附著於纖維氈上的銀顆粒。 The dried fiber mat was placed in a high temperature furnace at a temperature of 400 ° C and filled with nitrogen for 90 minutes to crack the silver pieces into silver particles dispersed on the fiber mat.

將附有銀顆粒的纖維氈研磨、粉碎與過篩,而得到一承載有銀顆粒的活性碳纖維主體層(銀顆粒及活性碳纖維主體層的整體稱作為「組成物結構」)。 The fiber mat with the silver particles is ground, pulverized, and sieved to obtain an activated carbon fiber main layer (the silver particles and the activated carbon fiber main layer collectively referred to as a "composition structure") carrying silver particles.

本製備例的組成物結構具有以下特徵:BET比表面積約為1,380m2/g、密度約為2.0425/m3、碳含量約為75wt%、銀含量約為0.072wt%;組成物結構中的主體層具有以下特徵:長度約為0.1mm、直徑約為6.0μm、孔洞直徑約為2.23nm;組成物結構中的銀顆粒具有以下特徵:在水中的析出量約為13.52ppm。 The composition structure of this preparation example has the following characteristics: a BET specific surface area of about 1,380 m 2 /g, a density of about 2.0425 / m 3 , a carbon content of about 75 wt%, and a silver content of about 0.072 wt%; The bulk layer has the following features: a length of about 0.1 mm, a diameter of about 6.0 μm, and a pore diameter of about 2.23 nm; the silver particles in the composition structure have the following characteristics: the amount of precipitation in water is about 13.52 ppm.

<製備例4> <Preparation Example 4>

於真空環境下,將以植物製成的活性碳顆粒浸泡在濃度0.008M的硝酸銀水溶液,並於50rpm轉速下旋轉混合2小時,以讓銀離子還原成附著於活性碳顆粒上的銀塊。乾燥附有銀塊的活性碳顆粒,以去除其殘留的水分。 The activated carbon particles made of plants were immersed in a silver nitrate aqueous solution having a concentration of 0.008 M in a vacuum atmosphere, and were rotationally mixed at 50 rpm for 2 hours to reduce silver ions to silver nuggets attached to the activated carbon particles. The activated carbon particles with silver blocks are dried to remove residual moisture.

於充滿氮氣的氛圍下,以4℃/分鐘的升溫速度加熱乾燥後的活性碳顆粒至600℃,持溫約60分鐘,最後以10℃/分鐘的降溫速度冷卻乾燥後的活性碳顆粒至室溫,以讓銀塊裂解成分散附著於活性碳顆粒上的銀顆粒。 The dried activated carbon particles were heated to 600 ° C at a heating rate of 4 ° C / min under a nitrogen atmosphere, and the temperature was maintained for about 60 minutes. Finally, the dried activated carbon particles were cooled to a chamber at a cooling rate of 10 ° C / minute. The temperature is such that the silver block is cleaved into silver particles dispersed on the activated carbon particles.

水洗附有銀顆粒的活性碳顆粒後,於120℃下乾燥水洗後的活性碳顆粒。 After washing the activated carbon particles to which silver particles were attached, the washed activated carbon particles were dried at 120 °C.

將乾燥後的活性碳顆粒研磨、粉碎與過篩,而得到一承載有銀顆粒的活性碳粉主體層(銀顆粒及活性碳粉主體層的整體稱作為「組成物結構」)。 The dried activated carbon particles are ground, pulverized, and sieved to obtain an active carbon powder main layer (silver particles and an active carbon powder main layer collectively referred to as a "composition structure") carrying silver particles.

本製備例的組成物結構具有以下特徵:BET比表面積約為1,024m2/g、碳含量約為73.54wt%、銀含量約為0.22wt%;組成物結構中的主體層具有以下特徵:粒徑約為0.1mm以下、孔洞直徑約為2.48nm;組成物結構中的銀顆粒具有以下特徵:粒徑約為100至300nm、在水中的析出量約為30.49ppm。 The composition structure of this preparation example has the following characteristics: a BET specific surface area of about 1,024 m 2 /g, a carbon content of about 73.54 wt%, and a silver content of about 0.22 wt%; the main layer in the composition structure has the following characteristics: The diameter is about 0.1 mm or less and the diameter of the pores is about 2.48 nm; the silver particles in the composition structure have the following characteristics: a particle diameter of about 100 to 300 nm and a precipitation amount in water of about 30.49 ppm.

<比較例1> <Comparative Example 1>

將一如製備例1使用的聚丙烯腈系活性碳纖維布研磨、粉碎與過篩,而得到一長度約為0.1mm的活性碳纖維主體層。 The polyacrylonitrile-based activated carbon fiber cloth used in Preparation Example 1 was ground, pulverized, and sieved to obtain an active carbon fiber main layer having a length of about 0.1 mm.

<比較例2> <Comparative Example 2>

將一具有以下性質的聚丙烯腈系活性碳纖維氈研磨、粉碎與過篩,而得到一長度約為0.1mm的活性碳纖維主體層:氈重為100g/m2、BET比表面積為600m2/g、孔洞直徑為2.07nm、密度為1.932g/m3、碳含量為86wt%、銀含量為0wt%。 A polyacrylonitrile-based activated carbon fiber mat having the following properties is ground, pulverized and sieved to obtain an active carbon fiber main layer having a length of about 0.1 mm: a felt weight of 100 g/m 2 and a BET specific surface area of 600 m 2 /g. The pore diameter was 2.07 nm, the density was 1.932 g/m 3 , the carbon content was 86 wt%, and the silver content was 0 wt%.

<比較例3> <Comparative Example 3>

將一如製備例4使用的活性碳顆粒研磨、粉碎與過篩,而得到一具有以下特徵的活性碳粉主體層:粒徑約為0.1mm以下、BET比表面積約為1,135m2/g、碳含量約為84.24wt%、孔洞直徑約為2.49nm。 The activated carbon particles used in Preparation Example 4 were ground, pulverized and sieved to obtain an active carbon powder main layer having a particle diameter of about 0.1 mm or less and a BET specific surface area of about 1,135 m 2 /g. The carbon content is about 84.24% by weight and the pore diameter is about 2.49 nm.

<分析例> <Analysis example>

請參閱表1,係列示著製備例1至4的組成物結構、比較例1及2的活性碳纖維主體層、以及比較例3的活性碳粉主體層對不同菌種的滅菌效果。表中代表滅菌效果的「滅菌率」是根據美國紡織品 染化工作者協會(American Association of Textile Chemists and Colorists,ATCC)100-1998測試方法測得的。 Referring to Table 1, the series shows the compositional structures of Preparation Examples 1 to 4, the activated carbon fiber main layers of Comparative Examples 1 and 2, and the activated carbon powder main layer of Comparative Example 3 for the sterilization effects of different strains. The "sterilization rate" representing the sterilization effect in the table is based on American textiles. Measured by the American Association of Textile Chemists and Colorists (ATCC) 100-1998 test method.

從上表可看出,製備例1之組成物結構中的主體層來源與比較例1的主體層來源雖為相同,但由於製備例1之組成物結構更有銀顆粒,因此製備例1之組成物結構對大腸桿菌、幽門螺旋桿菌、金黃色葡萄球菌及肺炎桿菌的滅菌效果明顯優於比較例1的主體層。 As can be seen from the above table, the source layer of the composition of the preparation example 1 was the same as the source layer of the comparative example 1, but since the composition of the preparation example 1 had silver particles, the preparation example 1 was The sterilizing effect of the composition structure on Escherichia coli, Helicobacter pylori, Staphylococcus aureus and Klebsiella pneumoniae was significantly better than that of the main body layer of Comparative Example 1.

從上表另可看出,製備例4之組成物結構中的主體層來源與比較例3的主體層來源雖為相同,但由於製備例4之組成物結構更有銀顆粒,因此製備例4之組成物結構對大腸桿菌、綠膿桿菌、金黃色葡萄球菌、幽門螺旋桿菌及肺炎桿菌的滅菌效果明顯優於比較 例3的主體層。 As can be seen from the above table, the source layer of the composition of the preparation example 4 was the same as the source layer of the comparative example 3, but since the composition of the preparation example 4 had silver particles, the preparation example 4 was prepared. The composition of the composition is significantly better than the comparison of the sterilization effect of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Helicobacter pylori and Klebsiella pneumoniae. The main layer of Example 3.

如第四、五圖所示,明顯地觀察到製備例3之組成物結構中的主體層可分別吸附大腸桿菌及幽門螺旋桿菌。銀顆粒會釋放出銀離子,特別是在水中,如此銀離子可與被吸附及/或未吸附之大腸桿菌或幽門螺旋桿菌之酵素中的硫醇基(-SH)結合,而讓酵素失活並有效地殺除大腸桿菌或幽門螺旋桿菌。 As shown in the fourth and fifth figures, it was apparent that the host layer in the composition structure of Preparation Example 3 can adsorb Escherichia coli and Helicobacter pylori, respectively. Silver particles release silver ions, especially in water, so that silver ions can bind to the thiol group (-SH) in the adsorbed and/or unadsorbed E. coli or Helicobacter pylori enzymes, leaving the enzyme inactive. And effectively kill E. coli or Helicobacter pylori.

綜合上述實施例的說明,證實了本創作的組成物結構可抑制腸胃道細菌的感染,而有作為抑制腸胃道細菌感染之藥物的潛力。另一方面,製成主體層及活性顆粒的材料為可食用的,因此本創作的組成物結構作為抑制腸胃道細菌感染的藥物時,不會對投予此藥物的個體產生毒副作用及/或抗藥性。 In combination with the above description of the examples, it was confirmed that the composition of the present composition can inhibit the infection of gastrointestinal bacteria and has the potential as a drug for inhibiting bacterial infection of the gastrointestinal tract. On the other hand, the material for forming the main layer and the active particles is edible, and therefore, the composition of the present composition, as a drug for inhibiting gastrointestinal bacterial infection, does not cause toxic side effects and/or to individuals who administer the drug. Drug resistance.

惟,以上所述者,僅為本創作之較佳實施例,但不能以此限定本創作實施之範圍;故,凡依本創作申請專利範圍及創作說明書內容所作之簡單的等效變化與修飾,皆應仍屬本創作專利涵蓋之範圍內。 However, the above-mentioned ones are only preferred embodiments of the present invention, but the scope of the present invention cannot be limited thereto; therefore, the simple equivalent changes and modifications made by the scope of the patent application and the content of the creation manual are All should remain within the scope of this creation patent.

(1)‧‧‧主體層 (1) ‧ ‧ main body

(11)‧‧‧孔洞 (11)‧‧‧ holes

(2)‧‧‧活性顆粒 (2) ‧‧‧active granules

Claims (9)

一種用於抑制腸胃道細菌感染的組成物結構,係包括:一主體層,係由碳質材料所製成的,且具有半徑大於0nm而未超過2.5nm的孔洞;以及一活性顆粒,係承載於該主體層的一表面,且係由銀、金、鋁、鋅、銅及二氧化鈦所組成之群組所製成的。 A composition for inhibiting bacterial infection of the gastrointestinal tract, comprising: a bulk layer made of a carbonaceous material and having pores having a radius greater than 0 nm and not exceeding 2.5 nm; and an active particle carrying It is made on a surface of the main body layer and is made up of a group consisting of silver, gold, aluminum, zinc, copper and titanium dioxide. 如申請專利範圍第1項所述之組成物結構,其中該碳質材料係選自於由活性碳纖維、活性碳粉、木炭、竹炭粒、碳黑、石墨粉、膨脹石墨粉及酚醛樹脂或人造樹脂製成的碳粉所組成的群組。 The composition structure of claim 1, wherein the carbonaceous material is selected from the group consisting of activated carbon fiber, activated carbon powder, charcoal, bamboo charcoal, carbon black, graphite powder, expanded graphite powder, and phenolic resin or artificial A group consisting of toner made of resin. 如申請專利範圍第1項所述之組成物結構,其中該主體層的比表面積係為400至2,500m2/g。 The composition structure of claim 1, wherein the body layer has a specific surface area of 400 to 2,500 m 2 /g. 如申請專利範圍第1項所述之組成物結構,其中該碳質材料為活性碳纖維時,該主體層的形狀係為圓柱狀,且其長度係為大於0nm而未超過0.1mm。 The composition structure according to claim 1, wherein when the carbonaceous material is activated carbon fiber, the bulk layer has a cylindrical shape and a length of more than 0 nm and less than 0.1 mm. 如申請專利範圍第1項所述之組成物結構,其中該碳質材料為活性碳纖維時,該主體層的形狀係為圓柱狀,且其直徑係為大於0μm而未超過10μm。 The composition structure according to claim 1, wherein when the carbonaceous material is activated carbon fiber, the body layer has a cylindrical shape and a diameter of more than 0 μm and not more than 10 μm. 如申請專利範圍第1項所述之組成物結構,其中該活性顆粒的粒徑係為1nm至500μm。 The composition structure according to claim 1, wherein the active particles have a particle diameter of from 1 nm to 500 μm. 如申請專利範圍第1項所述之組成物結構,其中以該主體層的重量為基準,該活性顆粒的重量百分比係為0.001至15wt%。 The composition structure according to claim 1, wherein the active particles are 0.001 to 15% by weight based on the weight of the main layer. 如申請專利範圍第1項所述之組成物結構,其中該活性顆粒在水 中的析出量係為大於0ppm而未超過100ppm。 The composition structure of claim 1, wherein the active particles are in water The amount of precipitation in the system is more than 0 ppm and not more than 100 ppm. 如申請專利範圍第1項所述之組成物結構,係用於抑制大腸桿菌、金黃色葡萄球菌或幽門螺旋桿菌的感染。 The composition structure as described in claim 1 is for inhibiting infection of Escherichia coli, Staphylococcus aureus or Helicobacter pylori.
TW102210595U 2013-06-05 2013-06-05 Composition structure for inhibiting bacterial infection of gastrointestinal tract TWM473840U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW102210595U TWM473840U (en) 2013-06-05 2013-06-05 Composition structure for inhibiting bacterial infection of gastrointestinal tract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW102210595U TWM473840U (en) 2013-06-05 2013-06-05 Composition structure for inhibiting bacterial infection of gastrointestinal tract

Publications (1)

Publication Number Publication Date
TWM473840U true TWM473840U (en) 2014-03-11

Family

ID=50822702

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102210595U TWM473840U (en) 2013-06-05 2013-06-05 Composition structure for inhibiting bacterial infection of gastrointestinal tract

Country Status (1)

Country Link
TW (1) TWM473840U (en)

Similar Documents

Publication Publication Date Title
CN103316043B (en) Containing the medicinal usage of the compositions of carbonaceous material and active particle
Tran et al. Nanomaterial‐based treatments for medical device‐associated infections
Bąkowski et al. Silver and zinc nanoparticles in animal nutrition–a review
Zhang et al. Antibacterial, anti-inflammatory and neuroprotective layer-by-layer coatings for neural implants
CN104544446A (en) Lung-heat-clearing anti-haze beverage and preparation method thereof
CN103316044B (en) For suppressing the compositions structure of intestines and stomach bacteriological infection
TWI471136B (en) Pharmaceutical use of a composition including a carbonaceous material and an active particle
CN105979933A (en) Pharmaceutical preparation and method of its production and use
CN114406281A (en) Method for preparing gold nanoparticles by reduction of plant polyphenol and application
TWM473840U (en) Composition structure for inhibiting bacterial infection of gastrointestinal tract
CN114767722B (en) Medicinal carbon dot modified probiotic preparation and preparation method and application thereof
CN105708046A (en) Preparation method of sterilization insole
TWI482632B (en) Pharmaceutical carrier and drug structure using the same
JP6719715B2 (en) Medicine to treat or prevent colorectal cancer
Tanabe et al. Aloe barbadensis Mill. ex vitro autotrophic culture
CN205432370U (en) Shoe -pad disinfects
CN106727351A (en) Amoxicillin micro-capsule dry suspensoid agent and preparation method thereof
TWI644686B (en) Oral poison adsorbent and preparation method thereof
CN106675838A (en) Special laundry detergent with functions of removing bacteria and formaldehyde for infants
Tan et al. Functionalized Rhodium Nanoparticles as Antimicrobial Agents for Treatment of Drug‐Resistant Skin and Soft Tissue Infections
GB1581984A (en) Antidiarrhoea medicament
CN116549418B (en) Nanoparticle for resisting postoperative infection and recurrence of gastric cancer as well as preparation method and application thereof
CN105343129A (en) Poisonous snakes drug and its production method
CN104666342A (en) Adsorbent capable of reducing in vivo urotoxin
CN106377763B (en) Multi-purpose sterilizing and cleaning spray and its application

Legal Events

Date Code Title Description
MM4K Annulment or lapse of a utility model due to non-payment of fees